IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein
✍ Scribed by Favorov, M. O.; Khudyakov, Y. E.; Mast, E. E.; Yashina, T. L.; Shapiro, C. N.; Khudyakova, N. S.; Jue, D. L.; Onischenko, G. G.; Margolis, H. S.; Fields, H. A.
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 926 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
To develop an enzyme immunoassay (EIA) for IgM antibody t o hepatitis E virus (HEW (IgM anti-HEV) and IgG antibody t o HEV (IgG anti-HEV), a synthetic gene encoding several liner immunodominant antigenic epitopes f r o m HEV structural proteins was assembled as a chimeric recombinant mosaic protein (Mpr) with glutathione Stransferase and used as an immunodiagnostic target. In addition, a neutralization confirmation test was developed using individual synthetic peptides. Among 61 4 patients with acute hepatitis from 10 geographically distinct outbreaks, IgG anti-HEV was found in 546 (88.9%), with a range of 77-100% depending o n the outbreak. Of 130 patients tested for IgM anti-HEV, 126 (96.9%) were positive. Among patients tested within 4 months of onset o f jaundice, 37/37 (100%) were IgG anti-HEV positive. For patients from w h o m sera were collected 1-16 days after onset of jaundice, the geometric mean IgG titer (GMT) was 1:47,000; the GMT increased t o 1:70,710 30-40 days after onset o f jaundice and decreased t o 1:1,778 3-4 months after the onset of jaundice. For patients tested 6-8 months after onset of jaundice, 11/12 (92%) were IgG anti-HEV positive, and the GMT was 1:2,908. IgM anti-HEV was detected in 43/43 (100%) sera collected 1-40 days after onset of jaundice, and the GMTfor IgM anti-HEV was 1:10,000 at that time. For sera collected 3-4 and 6-12 months after onset of jaundice, 7/14 (SOYO) and 5/12 (40%) respectively, were IgM anti-HEV positive. In conclusion, an artificial m osaic protein composed o f linear antigenic epitopes from open reading frame 2 (ORF2) and ORF3 of HEV has been successfully applied t o the development of a sensitive and specific EIA for the detection of IgG and IgM anti-HEV activity. These assays were used for the verification of 8 1996 WILEY-LISS. INC.
HEV infection i n outbreak settings and for the diagnosis o f HEV infection in sporadic cases.